NEW YORK, June 7 (GenomeWeb News) - ProMetic Life Sciences closed a private placement of 29.6 million subordinate voting shares valued at CA$10.8 million ($9.8 million) with JPMorgan and Third Point, the biopharmaceutical company said today. 

The shares were priced at CA$.365 per share.

The funds will be used to develop PBI-1402, an orally active drug for the treatment of anemia in cancer patients undergoing chemotherapy, as well as for general corporate purposes.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.